Pharmaceutical composition containing liposomes for treating cancer

• US 20050158375A1
• Filed: 03/14/2005
• Published: 07/21/2005
• Est. Priority Date: 11/15/2002
• Status: Abandoned Application

• Current Assignee: Nipro Corporation
• Original Assignee: Nipro Corporation
• Inventors: Sakuragi, Shiho, Yokoe, Jun-ichi, Ogawara, Ken-ichi, Sato, Makoto, Kai, Toshiya, Higaki, Kazutaka, Kimura, Toshikiro
• Application Number:
  US11/078,502
• Publication Number:
  US 20050158375A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543

Abstract

The present invention provides liposome-containing drug administration carriers that have improved residence time in the blood and improved migration into tumor cells as compared with conventional ones and that have reduced accumulation in the heart, and a pharmaceutical composition for treating a cancer that includes liposomes containing an antitumor active substance and having polyalkylene glycol and albumin bound thereto and that can be incorporated in large amounts in the cancer cells.

Claims

1. A pharmaceutical composition for treating a cancer, which comprises a liposome combined with a polyalkylene glycol and albumin, and an antitumor active substance, and which can be incorporated in a large amount in cancer cells.

2. The pharmaceutical composition according to claim 1, wherein the antitumor active substance is an antitumor antibiotic.

3. The pharmaceutical composition according to claim 2, wherein the antitumor antibiotic is an anthracycline antibiotic antitumor agent.

4. The pharmaceutical composition according to claim 3, wherein the anthracycline antibiotic antitumor agent is doxorubicin or a salt thereof.

5. The pharmaceutical composition according to claim 1, wherein the albumin is a genetic recombinant human serum albumin.

6. The pharmaceutical composition according to claim 1, wherein a content of the albumin is about 0.0001 to about 10 mol % based on the total amount of lipid constituting the liposome.

7. The pharmaceutical composition according to claim 1, wherein a volume average particle size of the liposome is about 10 to about 5,000 nm.

8. The pharmaceutical composition according to claim 1, wherein the polyalkylene glycol has a molecular weight of about 200 to about 4,000,000.

9. The pharmaceutical composition according to claim 1, wherein the polyalkylene glycol is polyethylene glycol.

10. The pharmaceutical composition according to claim 1, wherein the composition is an injection agent.

11. A method of treating a cancer, characterized by parenterally administering the pharmaceutical composition defined in claim 1.

12. A method of treating a cancer according to claim 11, wherein, the pharmaceutical composition is parenterally administered.